You are in the main area:Organization
Headerimage for: ViroLab

ViroLab

A Virtual Laboratory for Infectious Diseases

 

General Project Information:

Type: STREP (Specific Targeted Research Project)

Contract No.: IST-027446



Project Coordinator: Prof. Peter Sloot (UvA)

Technical Manager: Dr. Marian Bubak (AGH)



Start: 01. March 2006

End: 31. August 2009

Summary:

The ViroLab project is funded by the European Commission in the 6th Framework Programme for Research and Technological Development in the area of integrated biomedical information for better health.

The mission of ViroLab is to provide researchers and medical doctors in Europe with a Virtual Laboratory for Infectious Diseases that facilitates medical knowledge discovery and decision support. To this end a virtual laboratory will be developed enabling easy access to distributed resources as well as sharing, processing and analysing virological, epidemiological, clinical and experimental data.

As a prototype for this virtual laboratory for infectious diseases, the problem of HIV drug resistance will be used. The virtual laboratory will integrate the biomedical information from viruses (proteins and mutations), patients (e.g. viral load) and literature (drug resistance experiments) resulting in a rule-based distributed decision support system for drug ranking. In addition ViroLab will include advanced tools for (bio) statistical analysis, visualization, modelling and simulation, enabling prediction of the temporal virological and immunological response of viruses with complex mutation patterns for drug therapy.



The main objectives of ViroLab can be summarized as followed:


  • To develop a virtual organization, providing the "glue" for binding the various components of the ViroLab Virtual Laboratory;
  • To develop a virtual laboratory system infrastructure for transparent workflow, data access, experimental execution and collaboration support;
  • To virtualize and enhance state-of-art in genotype resistance inetrpretation tools and integrate them into the virtual laboratory;
  • To establish epidemiological validation that ViroLab correctly and quantantitavely predicts virological and immunological outcome and to disseminate the results of ViroLab to European stakeholds.

 

ISIS' main contributions:

  • Overall design and architecture of the virtual laboratory infrastructure
  • Data access infrastructure for connecting distributed (bio)medical data resources
  • (Bio)medical database integration
  • Dynamic access control management for distributed data resources
  • Data mining to support medical scientists during their studies
  • Project dissemination and exploitation leadership in collaboration with the Chair of Industrial Goods Marketing and Supply Management of University of Stuttgart

 

Partner:

University College London, United Kingdom
Gridwisetech, Poland
ACK Cyfronet AGH, Poland
Eotvos Lorand University, Hungary
Catholic University of Leuven, Belgium
IRSICAIXA Foundation, Spain
Catholic University of Rome, Italy
University of Brescia, Italy
University of Stuttgart, Germany
University of Amsterdam, The Netherlands
University Medical Centre Rotterdam, Erasmus MC, The Netherlands

Official Website:  http://www.virolab.org

Contact at HLRS:  Matthias Assel